Alto Neuroscience Valuation Multiples

Alto Neuroscience Overview

About Alto Neuroscience

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Founded

2019

HQ

Employees

76

Website

altoneuroscience.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

EBITDA: ($77M)

EV

$563M

Valuation Multiples

Multiples.vc

Start free trial

Alto Neuroscience Financials

Alto Neuroscience reported last 12-month revenue of — and negative EBITDA of ($77M).

In the same LTM period, Alto Neuroscience generated — in gross profit, ($77M) in EBITDA losses, and had net loss of ($71M).

Alto Neuroscience P&L

In the most recent fiscal year, Alto Neuroscience reported revenue of — and EBITDA of ($60M).

Alto Neuroscience expects next 12-month revenue of XXX and NTM EBITDA of XXX

Alto Neuroscience Stock Performance

Alto Neuroscience has current market cap of $716M, and enterprise value of $563M.

Alto Neuroscience's stock price is $22.40.

Alto Neuroscience Valuation Multiples

Alto Neuroscience trades at (7.3x) EV/EBITDA.

Alto Neuroscience Financial Valuation Multiples

As of April 11, 2026, Alto Neuroscience has market cap of $716M and EV of $563M.

Equity research analysts estimate Alto Neuroscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Alto Neuroscience has a P/E ratio of (10.1x).

Alto Neuroscience Margins & Growth Rates

Alto Neuroscience's revenue in the last fiscal year grew by —.

Alto Neuroscience's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.9M for the same period.

Alto Neuroscience Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Alto Neuroscience M&A Activity

Alto Neuroscience acquired XXX companies to date.

Last acquisition by Alto Neuroscience was on XXXXXXXX, XXXXX. Alto Neuroscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Alto Neuroscience Investment Activity

Alto Neuroscience invested in XXX companies to date.

Alto Neuroscience made its latest investment on XXXXXXXX, XXXXX. Alto Neuroscience invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).